Window of Opportunity trials for biomarker discovery in breast cancer-Reference-Cited by-同舟云学术

Window of Opportunity trials for biomarker discovery in breast cancer

Published:2019-11 Issue:6 Volume:31 Page:486-492
ISSN:1040-8746
Container-title:Current Opinion in Oncology
language:en
Short-container-title:

Author:

Arnedos Monica,Roulleaux Dugage Matthieu,Perez-Garcia Jose,Cortes Javier

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cancer Research,Oncology

Reference34 articles.

1. Genomic characterization of metastatic breast cancers;Bertucci;Nature,2019

2. Peri-operative aromatase inhibitor treatment in determining or predicting longterm outcome in early breast cancer – the POETIC∗ Trial (CRUK/07/015);Robertson;Clin Cancer Res,2018

3. A randomized phase II presurgical trial of weekly low-dose tamoxifen versus raloxifene versus placebo in premenopausal women with estrogen receptor-positive breast cancer;Serrano;Breast Cancer Res,2013

4. Close and stable relationship between proliferation and a hypoxia metagene in aromatase inhibitor-treated ER-positive breast cancer;Ghazoui;Clin Cancer Res,2011

5. Modulation of Rb phosphorylation and antiproliferative response to palbociclib: the preoperative-palbociclib (POP) randomized clinical trial;Arnedos;Ann Oncol,2018

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Endocrine therapy for early breast cancer in the era of oral selective estrogen receptor degraders: challenges and future perspectives;Current Opinion in Oncology;2024-08-13

2. The anti-proliferative effects of a frankincense extract in a window of opportunity phase ia clinical trial for patients with breast cancer;Breast Cancer Research and Treatment;2024-01-09

3. AMEERA-4: a randomized, preoperative window-of-opportunity study of amcenestrant versus letrozole in early breast cancer;Breast Cancer Research;2023-11-10

4. Patritumab deruxtecan in untreated hormone receptor-positive/HER2-negative early breast cancer: final results from part A of the window-of-opportunity SOLTI TOT-HER3 pre-operative study;Annals of Oncology;2023-08

5. Identification of PIMREG as a novel prognostic signature in breast cancer via integrated bioinformatics analysis and experimental validation;PeerJ;2023-07-17